It has been shown that high levels of FETU-A can be considered a risk factor for insulin resistance, T2DM, CVD by inhibition of adiponectin expression, peroxisome proliferator-activated receptor-γ (PPARγ) or activating the toll-like receptor 4 (TLR-4), and as a factor reducing the risk of coronary artery disease [41]. Here, ADIPOQ is linked to type 2 diabetes mellitus.